INSTITUT CURIE & SIREDO ONCOLOGY CENTER
Institut Curie has been a recognized public utility foundation since 1921. Since its creation by Marie Curie, the missions of the institute are centered on Research, Care, and Transmission of knowledge. Institut Curie combines a state-of-the-art oncology hospital complex spread over three sites (Paris, Orsay and Saint Cloud) and an internationally renowned research center where more than 1201 researchers work in 88 research teams.
The international SIREDO Oncology Center (Care, Innovation, and Research in pediatric, adolescent and young adult oncology) was created in 2017 and is headed by Dr. Olivier Delattre. The center aims to improve patient’s care through extensive comprehensive studies of the biology of the young patient’s tumors. Researchers, Physicians and health care professionals are affected to this center, with the aim of facilitating interactions between researchers and doctors, from bench to bedside and reciprocally. Our main strength is our capacities to start from fundamental research, aimed at better understanding the biology and development of the tumors, including Neuroblastoma, Rhabdoïd tumors, sarcomas, medulloblastoma, retinoblastoma to preclinical and clinical studies.

PROGRAM OVERVIEW
We aim to recruit highly talented young scientists from all over the world who wish to pursue research projects in basic and translational pediatric cancer research. Through the research groups in SIREDO, and the outstanding multi-disciplinary scientific environment of Institut Curie Research Center, we provide access to cutting-edge research facilities and state-of-the-art labs.
The postdoctoral fellow can join one of the following research teams at SIREDO:
– Diversity and Plasticity of pediatric tumors headed by Dr. Olivier Delattre and focusing mainly on defining the molecular lesions and tumor cells plasticity in Ewing Sarcoma and Neuroblastoma
– Translational research in pediatric oncology headed by Dr. Gudrun Schleiermacher and Dr. Franck Bourdeaut, and aims at setting new biomarkers and/or druggable targets in Neuroblastoma and Rhabdoid Tumors
– Signaling in development and brain tumors headed by Dr. Olivier Ayrault with main interest in deciphering fundamental mechanisms related to the complex biology of Medullobastoma using an integrative multi-omics approach.
– Signaling and cancer progression headed by Dr. Celio Pouponnot and focusing on deregulated signaling pathways in Medulloblastoma Group3 as well as on the mechanisms of resistance to radiotherapy.

REQUIREMENTS
We expect successful candidates to hold a PhD and to bring a strong interest and broad expertise in the field of tumor development and resistance as evidenced by a doctoral and/or related postdoctoral experience. Affinity with genomics, cancer immunology, single cell analysis, proteomics and cell signaling is highly appreciated. In addition, we expect the Postdoctoral Researcher to have excellent communication skills, to be a good team player and to have a strong affinity with working in an interdisciplinary and international research environment.

CONTACT
You can contact the principal investigator of research group of your choice directly to learn more about the ongoing projects.
You can also directly apply to the program by sending your CV, a motivation letter as well as the name of three referees to Sandy Azzi-Hatem, scientific and business manager of SIREDO: sandy.azzi-hatem@curie.fr

Deadline: 15th June 2019